The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index.
Abstract
Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease-patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly-with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS (see Box 1), with the presence of an increasing number of factors associated with greater risk.9,30,32–34”
Citations
Cites
Items 201–281 of 281
März, W., Scharnagl, H., Abletshauser, C., Hoffmann, M. M., Berg, A., Keul, J., Wieland, H., & Baumstark, M. W. (2001) · Circulation · doi:10.1161/01.cir.103.15.1942 · Cited by 52
Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Nordin, C., Dahl, M., Eriksson, M., & Sjöberg, S. (1997) · The Lancet · doi:10.1016/s0140-6736(05)66238-1 · Cited by 50
Managing dyslipidemia in the high-risk patient
Stein, E. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02229-4 · Cited by 50
Hyperlipidemia and transplantation
Pirsch, J. D., D’Alessandro, A. M., SOLLINGER, H. W., Knechtle, S. J., Reed, A., Kalayoğlu, M., & Belzer, F. O. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v212s238 · Cited by 49
The potential for drug interactions with statin therapy in Ireland
Heerey, A. M., Barry, M. G., Ryan, M., & Kelly, A. (2000) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf03167690 · Cited by 48
Lowering effects of four different statins on serum triglyceride level
Branchi, A., Fiorenza, A. M., Rovellini, A., Torri, A., Muzio, F., Macor, S., & Sommariva, D. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050663 · Cited by 47
Pharmacological Effects of HMG CoA Reductase Inhibitors Other Than Lipoprotein Modulation
White, C. M. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007642 · Cited by 47
Holdaas, H., Hartmann, A., Stenstrøm, J., Dahl, K. J., Borge, M., & Pfister, P. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80028-1 · Cited by 46
Effect of simvastatin on the lipid profile of hemodialysis patients
Nishikawa, O., Mune, M., Miyano, M., Nishide, T., Nishide, I., Maeda, A., Kimura, K., Takahashi, T., Kishino, M., Tone, Y., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07157.x · Cited by 46
Argov, Z. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200010000-00006 · Cited by 46
Kuper, J. J., & DʼAprile, M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039030-00003 · Cited by 46
Igarashi, M., Takeda, Y., Mori, S., Ishibashi, N., 小松, 栄., Takahashi, K., Fuse, T., Yamamura, M., Kubo, K., Sugiyama, Y., et al. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701018 · Cited by 46
Beyond lipids — the role of the endothelium in coronary artery disease
Aengevaeren, W. R. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00250-6 · Cited by 45
Atorvastatin for protease inhibitor-related hyperlipidaemia
Murillas, J., Martín, T., Ramos, A., & Portero, J. L. (1999) · AIDS · doi:10.1097/00002030-199907300-00030 · Cited by 43
Rhabdomyolysis Associated with Concurrent Use of Simvastatin and Diltiazem
Peces, R., & Pobes, A. (2001) · Nephron · doi:10.1159/000046056 · Cited by 41
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection
Sahu, K. M., Sharma, R., Gupta, A., Gulati, S., AGARWAL, D., Kumar, A., & Bhandari, M. (2001) · Clinical Transplantation · doi:10.1034/j.1399-0012.2001.150305.x · Cited by 41
Meier, C. R., Stey, C., Brack, T., Maggiorini, M., Risti, B., & Krähenbühl, S. (1995) · PubMed · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Kotanko, P., Kirisits, W., & Skrabal, F. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000049053 · Cited by 39
Nishizawà, Y., Shoji, T., Emoto, M., Kawasaki, K., Konishi, T., Tabata, T., Inoue, T., & Morii, H. (1995) · PubMed · Cited by 39
Biotransformation of Pravastatin Sodium(I)
Kitazawa, E., Tamura, N., Iwabuchi, H., Uchiyama, M., Muramatsu, S., Takahagi, H., & Tanaka, M. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1457 · Cited by 37
Bandoh, T., Mitani, H., Niihashi, M., Kusumi, Y., Ishikawa, J., Kimura, M., Totsuka, T., Sakurai, I., & Hayashi, S. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00573-0 · Cited by 37
Appel, S., Rüfenacht, T., Kalafsky, G., Tetzloff, W., Kállay, Z., Hitzenberger, G., & Kutz, K. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80012-8 · Cited by 37
Frequency of creatine kinase elevation during treatment with fluvastatin
Benghozi, R., Bortolini, M., Jia, Y., Isaacsohn, J. L., Troendle, A. J., & Gonasun, L. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02209-3 · Cited by 36
Massive Rhabdomyolysis and Simvastatin
Bizzaro, N., Bagolin, E., Milani, L., Cereser, C., & Finco, B. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.8.1504 · Cited by 36
Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients
Bruckert, E., Lièvre, M., Giral, P., Crepaldi, G., Masana, L., Vrolix, M., Leitersdorf, E., & Dejager, S. (2003) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2003.02000.x · Cited by 35
Serebruany, V. L., Steinhubl, S. R., & Hennekens, C. H. (2003) · Circulation · doi:10.1161/01.cir.0000065125.50640.70 · Cited by 35
Sica, D. A., & Gehr, T. W. B. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200203000-00001 · Cited by 35
D’Agostino, R. B., Kannel, W. B., Stepanians, M. N., & D'Agostino, L. C. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90715-o · Cited by 34
Treatment of Hyperlipidemia in the Nephrotic Syndrome: The Effects of Pravastatin Therapy
Spitalewitz, S., Porush, J. G., Cattran, D. C., & Wright, N. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70180-4 · Cited by 33
Acute cholestatic hepatitis during simvastatin administration.
Ballare, M., Campanini, M., Catania, E., Bordin, G., Zaccala, G., & Monteverde, A. (1991) · PubMed · Cited by 31
Mibefradil, a Pharmacologically Distinct Calcium Antagonist
Ernst, M. E., & Kelly, M. W. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03110.x · Cited by 31
Karayan, L., Qiu, S., Bétard, C., Dufour, R., Roederer, G. O., Minnich, A., Davignon, J., & Genest, J. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.8.1258 · Cited by 31
Jacobson, T. A., & Amorosa, L. (1994) · American Journal of Cardiology · doi:10.1016/0002-9149(94)90629-7 · Cited by 29
Samuelsson, O. G., Attman, P., Knight‐Gibson, C., Mulec, H., Weiss, L. G., & Alaupovic, P. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29883 · Cited by 28
Cardiovascular disease: Much more aggressive in patients with type 2 diabetes
Chiquette, E., & CHILTON, R. J. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0037-z · Cited by 28
Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency
Lintott, C. J., Scott, R. S., Bremer, J. M., & Shand, B. I. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80027-x · Cited by 28
Alsheikh-Ali, A. A. A., Abourjaily, H. M., & Karas, R. H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02334-2 · Cited by 26
Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus
Tan, K. C. B., Janus, E. D., & Lam, K. S. L. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00471-3 · Cited by 25
‘Fire and forget?’ — pharmacological considerations in coronary care
Bottorff, M. B. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00252-x · Cited by 25
Peters, T. K., Mehra, M. R., & Muratti, E. N. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.340s · Cited by 24
Lipoprotein classes and coronary disease regression
Zambon, A., & Hokanson, J. E. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199808000-00008 · Cited by 24
Statins after cardiac transplantation: which statin, what dose, and how low should we go?
Ballantyne, C. M. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00125-x · Cited by 24
A drug interaction between troglitazone and simvastatin.
Lin, J. C., & Ito, M. K. (1999) · Diabetes Care · doi:10.2337/diacare.22.12.2104a · Cited by 23
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
Li, P. K.-T., Mak, T. W. L., Wang, A. Y.-M., Lee, Y. T., Leung, C. B., Lui, S., Lam, C. W. K., & Lai, K. N. (1995) · PubMed · Cited by 22
Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure.
Maschio, G., Oldrizzi, L., Rugiu, C., Biase, V. D., & Loschiavo, C. (1991) · PubMed · Cited by 20
Farnier, M., Bortolini, M., Salko, T., Freudenreich, M.-O., Isaacsohn, J. L., Troendle, A. J., & Gonasun, L. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03116-8 · Cited by 19
Cholesterol lowering in the older population: time for reassessment?
Kagansky, N., Levy, S., Berner, Y., Rimon, E., & Knobler, H. (2001) · QJM · doi:10.1093/qjmed/94.9.457 · Cited by 19
Dual hepatic metabolism of cerivastatin--clarifications.
Guyton, J. R., Dujovne, C. A., & Illingworth, D. R. (1999) · PubMed · Cited by 19
Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
Watts, G. F. (2001) · Trials · doi:10.1186/cvm-2-3-118 · Cited by 18
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia
Hoogerbrugge (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00352.x · Cited by 18
Effects of Fluvastatin on Hyperlipidemia after Renal Transplantation: Influence of Steroid Therapy
Austen, J. L., Shifrin, F. A., Bartucci, M. R., Knauss, T. C., Schulak, J. A., & Hricik, D. E. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603001204 · Cited by 17
Pharmacokinetics of Fluvastatin in Subjects with Renal Impairment and Nephrotic Syndrome
Appel‐Dingemanse, S., Smith, T., & Merz, M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011346 · Cited by 15
Davidson, M. H. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600302 · Cited by 15
Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
Prata, M. M., Ac, N., Pinto, Am, C., Vicente, O., Mc, R., & Mj, M. (1994) · PubMed · Cited by 15
Knoll, R. W., Ciafone, R. A., & Galen, M. A. (1993) · PubMed · Cited by 15
Földes, K., Makláry, E., Vargha, P., Janssen, J., Jaray, J., Perner, F., & Gerő, L. (1998) · Transplant International · doi:10.1007/s001470050428 · Cited by 14
Ahmad, S. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90572-q · Cited by 14
Lemay, A., Dodin, S., Turcot, L., Déchêne, F., & Forest, J. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00244-4 · Cited by 13
Endocrine and metabolic abnormalities following kidney transplantation
Hörl, W. H., Riegel, W., Wanner, C., Haag–Weber, M., Schollmeyer, P. J., Wieland, H., & Wilms, H. (1989) · Journal of Molecular Medicine · doi:10.1007/bf01717348 · Cited by 13
Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis?
Gutierrez, C. (2001) · PubMed · Cited by 13
Chan, P., Huang, T., Tomlinson, B., Lee, C., & Lee, Y. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04327.x · Cited by 12
Narita, Y., Kitazoe, Y., Kurihara, Y., Okuhara, Y., TAKAMATSU, K., Saito, N., & Doi, Y. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050319 · Cited by 11
Rhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporine
Blaison, G., Weber, J., Sachs, D., Korganow, A., Martin, T., Kretz, J., & Pasquali, J. L. (1992) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(05)80013-x · Cited by 11
The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients.
Ghods, A. J., Milanian, I., Arghani, H., & Ghadiri, G. (1995) · PubMed · Cited by 11
Romeu, J., Sirera, G., Rêgo, M. J. B. D. M., Negredo, E., Bonjoch, A., Jou, A., Cruz, L. A. B., & Clotet, B. (1999) · Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy · Cited by 11
Umbilical vein cardiac catheterization
Saxena, A., Vohra, P., Jain, Y. K., Narayanan, S. N., & Kumar, R. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90570-y · Cited by 10
Acute cholestasis during long-term treatment with fluvastatin in a nephrotic patient
Gascón, A., Zabala, S., & Iglesias, E. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.4.1038a · Cited by 10
Hosokawa, R., Nohara, R., Linxue, L., Tamaki, S., Hashimoto, T., Tanaka, M., Miki, S., & Sasayama, S. (2000) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.64.177 · Cited by 10
Interaction between ritonavir and statins
Piliero, P. J. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01034-3 · Cited by 9
Branchi, A., Fiorenza, A. M., Torri, A., Muzio, F., Berra, C., Colombo, E., Valle, E. D., Rovellini, A., & Sommariva, D. (2002) · PubMed · Cited by 8
Fluvastatin in the treatment of hypercholesterolemia in renal transplantation
Gómez, G., Alvarez, M. L. G., Errasti, P., Lavilla, F. J., García, N., Ballester, B., Garcı́a, I., & Purroy, A. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(99)00362-0 · Cited by 8
The use of statins after solid organ transplantation
Holdaas, H. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.8.1537 · Cited by 7
van Ypersele, C. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.8.1538 · Cited by 6
Malyszko, J. S., Małyszko, J. S., & Myśliwiec, M. (2000) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)01252-5 · Cited by 4
Tanaka, M., Itoh, K., Matsushita, K., Kitamura, K., Nonoguchi, H., & Tomita, K. (2002) · PubMed · Cited by 4
Moriguchi, E. H., Vieira, J. L., & Itakura, H. (2001) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(01)80423-2 · Cited by 3
Wo, R., Bg, J., & SCHWANDT, P. (1991) · PubMed · Cited by 3
(1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)90433-2 · Cited by 3
Ulcerative Keratitis among Users of Contact Lenses
(1990) · New England Journal of Medicine · doi:10.1056/nejm199003083221015 · Cited by 2
(2002) · PubMed
Research works printed but not linked: 10
- Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.
- Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917. · doi:10.1345/aph.10315 · Paper page
- Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
- Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31. · doi:10.1345/aph.10177 · Paper page
- Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.
- Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815. · DOI
- Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118. · DOI · Paper page
- Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.
- Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.
- Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Self-citationClinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K. A., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 238
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 160
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 156
Metadata
- Authors
- Corsini, A.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Corsini, Alberto
- ORCID
- Corsini, Alberto
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2003-05
- Volume
- 17
- Issue
- 3
- Pages
- 265-285
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2191544621
- Cited by
- 82
- References
- 286
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 5 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, drug safety, high cardiovascular risk, lipid-lowering therapy, drug interactions, myotoxicity, coronary artery disease, dyslipidemia, diabetes mellitus, hypertension, nephrotic syndrome, HIV, transplant recipients, elderly patients, statin pharmacokinetics
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Kidney Failure, Chronic, Rhabdomyolysis, Transplantation, HIV-1, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.